Viscosupplementation Market (2026 - 2036)

Viscosupplementation Market Size, Market Forecast and Outlook By FMI

In 2026, the viscosupplementation market was valued at USD 2,410.2 million. Based on Future Market Insights analysis, demand for viscosupplementation is estimated to grow to USD 4,188.9 million by 2036. FMI projects a CAGR of 5.7% during the forecast period.

Summary of Viscosupplementation market

• The market covers intra-articular joint injections used for lubrication, pain reduction, and conservative management of osteoarthritis across orthopedic settings.
• Demand is driven by the rising prevalence of knee osteoarthritis and increasing preference for non-surgical pain management therapies.
• Growth is supported by the shift toward outpatient and minimally invasive musculoskeletal treatments across ambulatory and specialist care centers.
• Adoption is increasing due to physician reliance on injection-based symptom relief and workflow-compatible treatment options.
• Three-injection knee hyaluronic acid products lead by product segment with a 47.8% share in 2026.
• Ambulatory surgical centers dominate by end user with a 32.3% share in 2026.
• China, Japan, and India are the fastest-growing markets, driven by rising osteoarthritis burden and expanding access to orthopedic care.
• The market is shaped by treatment regimen convenience, physician familiarity, and patient adherence considerations.
• Competition is influenced by product positioning, provider relationships, and established treatment protocols that limit switching behavior.
• The market outlook emphasizes expansion in outpatient care settings, physician education, and portfolio breadth to sustain long-term demand growth.

Absolute dollar growth of USD 1,778.7 million over the decade signals steady expansion rather than a demand reset. As per FMI, demand is expected to remain supported by the growing burden of knee osteoarthritis, wider preference for non-surgical pain management, and continued use of intra-articular therapies in patients seeking to delay invasive intervention. At the same time, reimbursement variation, physician preference differences, and treatment pathway standardization are expected to keep value growth measured across mature musculoskeletal care systems. “At Cipla, our focus continues to remain on moving up the innovation curve and delivering next-generation therapies that improve overall patient outcomes. With Ciplostem, our aim is to bring a scientifically validated cell therapy option into everyday clinical practice, which significantly reduces pain, preserves joint function and enhances mobility for up to 2 years after administration in knee OA.”

Based on FMI’s report, China (9.0% CAGR), Japan (8.5%), and India (7.9%) are expected to lead growth due to expanding osteoarthritis patient pools, improving orthopedic access, and stronger procedural adoption across outpatient settings. Italy (6.1%), France (5.7%), and the UK(5.6%) are expected to maintain healthy expansion through specialist-led treatment demand and broader use of joint preservation strategies. Mature markets such as the USA(3.9%) and Germany (4.0%) are expected to contribute mainly through repeat utilization and established physician familiarity, with growth constrained by mature treatment penetration and structured reimbursement discipline.

Viscosupplementation Market Definition

The market includes intra-articular viscosupplementation products used to improve joint lubrication, reduce pain, and support functional relief in osteoarthritis management, particularly in the knee. These products are sold to hospitals, ambulatory surgical centers, orthopedic clinics, retail channels, and related care settings to support conservative and procedure-based treatment pathways where hyaluronic acid-based joint injections are clinically indicated. The market includes single injection knee hyaluronic acid injections, three injection knee hyaluronic acid injections, five injection knee hyaluronic acid injections, and next generation steroid combination products used for routine osteoarthritis management. The market is driven by osteoarthritis treatment volumes, physician preference, regimen convenience, patient adherence considerations, and access across orthopedic care channels. The revenue stream is derived from sales of viscosupplementation injections across musculoskeletal and outpatient treatment settings.

Viscosupplementation Market Inclusions

The report provides global and regional market sizing, as well as a 10-year forecast from 2026 to 2036. The report also provides market sizing by product and end user, with country-level CAGR comparisons across key markets. The report also provides analysis on competitive positioning of key suppliers, channel-level demand patterns, and the influence of regimen design, treatment convenience, and physician adoption on supplier choice, as per FMI.

Viscosupplementation Market Exclusions

The scope does not include oral osteoarthritis supplements, pain medications, orthopedic implants, arthroscopy devices, and broader regenerative therapies not positioned as viscosupplementation products. Platelet-rich plasma, stem cell interventions, and unrelated injectable musculoskeletal therapies are also excluded. The scope also does not include non-hyaluronic acid joint care products not used in structured viscosupplementation pathways, but only viscosupplementation products used for patient-facing osteoarthritis management.

Viscosupplementation Market Research Methodology

• Primary Research: Interviews were carried out with orthopedic physicians, sports medicine specialists, ambulatory care providers, distributors, and procurement stakeholders to confirm treatment demand patterns and purchase behavior.
• Desk Research: Public data from regulatory bodies, musculoskeletal care publications, company materials, clinical references, and orthopedic treatment sources were analyzed to compare product positioning and usage trends.
• Market Sizing and Forecasting: A hybrid approach was created based on product regimen mapping, end-user demand patterns, and osteoarthritis treatment throughput, and then harmonized through volume and price triangulation.
• Data Validation and Update Cycle: Results were filtered for variance, tested for internal consistency, and assessed through structured peer review before distribution.

Segmental Analysis

Viscosupplementation Market Analysis by Product

Based on FMI’s report, three injection knee hyaluronic acid injections are estimated to hold 47.8% share in 2026. This lead position is supported by their balance between treatment durability, physician familiarity, and patient acceptance across knee osteoarthritis management pathways. Their larger share is being reinforced by established clinical use patterns, stronger comfort with multi-visit therapy sequencing, and the perception that the regimen offers a practical middle ground between convenience and sustained symptom relief.

• Established weekly regimen use: Three-injection regimens remain strongly represented because they are an established viscosupplementation format in knee osteoarthritis care. A 2024 randomized trial showed three once-weekly Hylan G-F 20 injections delivered pain relief lasting up to 26 weeks, reinforcing continued physician familiarity with this schedule. [2]
• Balanced efficacy and practicality: Recent comparative evidence suggests the three-injection format continues to offer a practical balance between treatment intensity and outcome durability. A 2024 study reported that triple low-dose high-molecular-weight HA injections improved WOMAC, VAS, and Lequesne scores more than a single high-dose injection.[3]
• Middle-ground regimen preference: Three injection knee hyaluronic acid injections hold the highest share because they offer a practical middle-ground regimen, combining broader physician comfort and manageable visit scheduling with a treatment format often viewed as more sustained than single-shot options without the burden of longer dosing courses.

Viscosupplementation Market Analysis by End User

Ambulatory surgical centers account for 32.3% share in 2026, based on FMI’s report, reflecting their role as an efficient setting for procedure-based musculoskeletal interventions and outpatient joint care. Their leading position is supported by growing patient preference for lower-complexity treatment environments, stronger alignment with injection-based orthopedic workflows, and the operational convenience of delivering viscosupplementation outside large hospital systems. Demand is therefore being concentrated in ASCs where throughput, convenience, and specialist access remain strong.

• Outpatient Orthopedic Care Alignment: Viscosupplementation fits well within ambulatory surgical center workflows because it is a scheduled, low-acuity, injection-based intervention used in knee osteoarthritis management, and recent EUROVISCO guidance continues to describe intra-articular hyaluronic acid as a commonly used office and outpatient treatment.[4]
• Shift Toward Ambulatory Settings: Ambulatory surgical centers continue to benefit from broader migration of orthopedic care into outpatient settings. Recent peer-reviewed studies show growing movement of musculoskeletal and joint-related procedures into ASCs, reinforcing these sites as strong hubs for non-hospital orthopedic interventions.[5]
• Channel suitability: Viscosupplementation use aligns closely with outpatient orthopedic management where non-surgical intervention is prioritized before advanced procedures.

Viscosupplementation Market Drivers, Restraints, and Opportunities

Future Market Insights analysis indicates that historical patterns point to a non-surgical orthopedic injectables category where demand is anchored in pain relief, mobility support, and delay of invasive intervention across osteoarthritis care pathways. Estimated valuation in 2026 is being supported by aging populations, increasing knee degeneration burden, and broader use of conservative treatment strategies within orthopedic and sports medicine environments, as per FMI.

While category demand is being restrained by reimbursement variation, debate around treatment durability, and competitive pressure from other pain-management approaches, value is being supported by outpatient care expansion, specialist-driven use, and greater patient willingness to pursue minimally invasive symptom relief. Based on FMI’s report, the forecast trajectory reflects a market where ambulatory treatment settings remain highly relevant, while suppliers are differentiated by regimen design, physician trust, and channel coverage strength.

• Conservative-Care: Demand is being supported as patients and providers continue to seek non-surgical options for knee osteoarthritis symptom management.
• Reimbursement-Led: Treatment adoption is being moderated where coverage inconsistency and affordability concerns affect injection uptake.
• Outpatient Expansion: Demand is being supported as more musculoskeletal care is being delivered through ambulatory and specialist orthopedic settings.

Regional Analysis

Based on the regional analysis, viscosupplementation market is segmented into North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa across 40+ countries. Regional performance is assessed using country-level demand signals tied to osteoarthritis burden, orthopedic care access, physician preference, and outpatient treatment penetration, as per FMI. The full report also offers market attractiveness analysis based on regional trends.

Country	CAGR
China	9.0%
Japan	8.5%
India	7.9%
Italy	6.1%
France	5.7%
United Kingdom	5.6%
Germany	4.0%
United States	3.9%

Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research

North America Viscosupplementation Market Analysis

North America is shaped by structured musculoskeletal care pathways and physician-led treatment selection, where product choice is influenced by reimbursement visibility, clinical familiarity, and suitability within non-surgical osteoarthritis management. Sanofi S.A. holds strong placement through product visibility and established orthopedic use across joint care channels. Bioventus LLC and Fidia Farmaceutici S.p.A. compete through focused viscosupplementation portfolios and specialist-driven market presence. Based on FMI’s report, demand remains anchored in established physician familiarity and repeat treatment utilization.

• United States: The demand for viscosupplementation in the United States is expected to grow at a CAGR of 3.9% during the forecast period of 2036. This is driven by established osteoarthritis treatment use, continued reliance on non-surgical symptom relief, and strong orthopedic specialist access, although this is tempered by mature treatment penetration and structured reimbursement discipline.

FMI’s report includes a detailed analysis of the growth in the North American region, along with a country-wise assessment that includes the United States. Readers can also find regional trends, regulations, and market growth based on different segments and countries in the North America region.

East Asia Viscosupplementation Market Analysis

East Asia continues to be a high-growth demand market, driven by rising osteoarthritis incidence, aging populations, and broader use of joint preservation strategies across orthopedic care settings. Regional demand is being strengthened by expanding specialist access, improving outpatient musculoskeletal care, and stronger patient preference for non-surgical mobility support. Based on FMI’s report, product adoption remains supported by treatment familiarity, growing procedure volumes, and better access to viscosupplementation across structured care channels.

• China: The viscosupplementation market in China is estimated to expand at a CAGR of 9.0% during the forecast period of 2036. This is being driven by rapid growth in osteoarthritis patient volumes, expanding orthopedic access, and rising willingness to pursue injection-based symptom management, with market dynamics influenced by broader treatment availability and urban specialist expansion.
• Japan: The demand for viscosupplementation in Japan is expected to grow at a CAGR of 8.5% during the forecast period of 2036. This is driven by an aging population, strong awareness of joint preservation approaches, and continued reliance on conservative osteoarthritis treatment pathways, although this remains shaped by mature physician guidance and structured treatment discipline.

The full report analyzes the viscosupplementation market across East Asia from 2021 to 2036, covering pricing, trends, and growth drivers in China, Japan, South Korea, and related regional markets. The assessment highlights trends that dictate regional demand and procurement behaviour.

South Asia & Pacific Viscosupplementation Market Analysis

South Asia & Pacific is being shaped by rising orthopedic care access, growing osteoarthritis recognition, and wider willingness to adopt minimally invasive symptom-control interventions. Supplier positioning in the region is influenced by treatment affordability, physician education, and channel access across developing musculoskeletal care networks. Based on FMI’s report, demand remains supported by urban treatment expansion and stronger integration of injection-based joint care into specialist practice.

• India: Demand for viscosupplementation in India is projected to rise at 7.9% CAGR through 2036. Growth is supported by expanding orthopedic care access, increasing patient awareness of non-surgical knee pain management, and rising use of injection-based treatment pathways across urban and secondary care environments.

The full report analyzes the viscosupplementation market across South Asia & Pacific from 2021 to 2036, covering pricing, trends, and growth drivers in India, ASEAN Countries, Australia & New Zealand, and Rest of South Asia. The assessment highlights trends that dictate regional demand and procurement behaviour.

Western Europe Viscosupplementation Market Analysis

Western Europe is physician-guided and quality-led, where treatment adoption is shaped by specialist practice patterns, patient preference for joint preservation, and careful use of non-surgical osteoarthritis therapies. Sanofi S.A., Seikagaku Corporation, and Ferring B.V. maintain relevance through product access, channel presence, and established use across orthopedic care environments. Use continues to be influenced by treatment discipline, reimbursement frameworks, and physician familiarity with injection-based mobility support. As per FMI, specialist-led demand and recurring patient management continue to govern treatment use across the region.

• Germany: Demand for viscosupplementation in Germany is projected to rise at 4.0% CAGR through 2036. Growth is supported by structured orthopedic care, stable use of non-surgical osteoarthritis management, and continued physician familiarity with injection-based treatment pathways.
• France: The demand for viscosupplementation in France is expected to grow at a CAGR of 5.7% during the forecast period of 2036. This is driven by specialist-led joint care demand, continued use of conservative osteoarthritis treatment, and broader acceptance of injection-based symptom relief across musculoskeletal care settings.
• Italy: The demand for viscosupplementation in Italy is expected to grow at a CAGR of 6.1% during the forecast period of 2036. This is driven by growing use of joint preservation strategies, rising orthopedic treatment demand, and wider physician acceptance of intra-articular pain management, although this remains influenced by treatment affordability and channel access.
• United Kingdom: The demand for viscosupplementation in the United Kingdom is expected to grow at a CAGR of 5.6% during the forecast period of 2036. This is driven by steady specialist demand and increasing preference for non-surgical musculoskeletal management, although this is filtered through treatment guidelines and structured pathway adoption.

FMI’s analysis of viscosupplementation market in Western Europe consists of country-wise assessment that includes Germany, the UK, France, Italy, Spain, BENELUX, Nordic Countries, and Rest of Western Europe. Readers can know various regulations and latest trends in the regional market.

Competitive Aligners for Market Players

The market structure remains moderately concentrated, with effective competition centered on suppliers capable of supporting clinically accepted viscosupplementation products, reliable orthopedic channel access, and differentiated regimen portfolios across joint care pathways. The data provided shows the presence of a leading participant in the market, with the rest of demand distributed across a focused set of orthopedic and specialty musculoskeletal companies. The key competitive factor is physician comfort with treatment response, regimen design, and repeat-use suitability, as product choice is filtered through specialist trust and patient management continuity. The product portfolio also reflects this emphasis, as three injection knee hyaluronic acid injections account for the leading share in the supplied segmentation, as indicated by FMI.

Companies with established orthopedic relationships, strong specialist education support, and product breadth across injection regimens carry structural advantages because buyer qualification is governed by physician familiarity, treatment consistency, and confidence in patient response across repeat care cycles. Scale leaders benefit from broader market access, stronger product awareness, and the ability to support multiple treatment settings under the same portfolio umbrella. Portfolio breadth across single injection, three injections, and five injection formats helps protect account positions when providers standardize around known viscosupplementation options. Suppliers with narrower reach or limited channel depth tend to compete through selective geographies, price responsiveness, or niche physician relationships, which can weaken their position during structured product conversion.

Customer concentration reinforces buyer leverage. Ambulatory surgical centers account for the largest end-user pool in the supplied segmentation, with orthopedic clinics and hospitals forming the next tier of demand. Large specialist networks commonly keep preferred products active, prioritize regimens that fit established musculoskeletal workflows, and favor suppliers with dependable availability across recurring patient volumes. Pricing power is therefore moderated for standard hyaluronic acid formats, with measured advantage retained only where regimen fit, physician preference, or treatment familiarity creates stronger channel preference, Future Market Insights analysis.

Recent Developments

• In December 2025, Cipla Limited has announced the launch of Ciplostem, an innovative allogeneic mesenchymal stromal cell (MSC) therapy for Knee Osteoarthritis (Knee OA), approved by the Drug Controller General of India (DCGI). Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III Knee OA and marks a significant advancement in Cipla’s entry into Orthobiologic medicine. [6]
• In December 2025, Synartro AB announced completion of dosing across all four cohorts in its phase 1/2a clinical study of SYN321 for knee osteoarthritis. The trial, conducted with Uppsala University Hospital, has enrolled 35 participants and is evaluating safety, tolerability, pharmacokinetics, and early efficacy, with full study completion expected in spring 2026.
• In July 2025, A real-world study demonstrates that a single intra-articular hyaluronic acid injection can significantly improve outcomes in advanced knee osteoarthritis. Over six months, patients showed ~50% reductions in pain scores and notable gains in function and stiffness, with no reported adverse events. The findings reinforce HA as a safe, non-surgical option, supporting its role in managing elderly patients delaying or unsuitable for surgery.
• In February 2024, IBSA UK an affiliate of IBSA Group, a global leader in innovative healthcare solutions, announced the launch of a range of products specifically addressing musculoskeletal conditions, with a focus on Osteoarthritis management – presenting SINOVIAL [7]

Key Players in Viscosupplementation Market

• Sanofi S.A.
• Zimmer Biomet Holdings Inc.
• Bioventus LLC
• Anika Therapeutics Inc.
• Fidia Farmaceutici S.p.A.
• Seikagaku Corporation
• Ferring B.V.
• Chugai Pharmaceutical Co. Ltd.
• LG Chem Life Sciences
• OrthogenRx
• Hanmi Pharm Co., Ltd.

Scope of the Report

Metric	Value
Quantitative Units	USD 2,410.2 million (2026) to USD 4,188.9 million (2036), at a CAGR of 5.7%
Market Definition	The viscosupplementation market comprises intra-articular injections used to improve joint lubrication, reduce pain, and support conservative osteoarthritis management, where demand is shaped by physician preference, treatment regimen design, and patient willingness to pursue non-surgical symptom relief across orthopedic care settings.
Product Segmentation	Single Injection Knee Hyaluronic Acid Injections, Three Injection Knee Hyaluronic Acid Injections, Five Injection Knee Hyaluronic Acid Injections, Next Generation (Steroid Combination)
End User Segmentation	Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Retail Pharmacies, Online Sales
Regions Covered	North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa
Countries Covered	United States, Canada, United Kingdom, Germany, France, China, Japan, South Korea, Brazil, Australia, India, and 40+ countries
Key Companies Profiled	Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Seikagaku Corporation, Ferring B.V., Chugai Pharmaceutical Co. Ltd., LG Chem Life Sciences OrthogenRx,   Hanmi Pharm Co., Ltd.
Forecast Period	2026 to 2036
Approach	Hybrid top down and bottom up market modeling validated through primary interviews with orthopedic and procurement stakeholders, supported by demand triangulation across osteoarthritis treatment volumes, care settings, and product adoption patterns, as per FMI.

Viscosupplementation Market Analysis by Segments

Product

• Single Injection Knee Hyaluronic Acid Injections
• Three Injection Knee Hyaluronic Acid Injections
• Five Injection Knee Hyaluronic Acid Injections
• Next Generation (Steroid Combination)

End User

• Hospitals
• Ambulatory Surgical Centers
• Orthopedic Clinics
• Retail Pharmacies
• Online Sales

Region

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• East Asia
  • China
  • Japan
  • South Korea
• South Asia & Pacific
  • India
  • ASEAN Countries
  • Australia & New Zealand
  • Rest of South Asia
• Western Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • BENELUX
  • Nordic Countries
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Hungary
  • Poland
  • Rest of Eastern Europe
• Middle East & Africa
  • Saudi Arabia
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Bibliography

• [1] Cipla Limited (2025) Cipla launches Ciplostem cell therapy for Knee Osteoarthritis in India.
• [2] PubMed Central. (2024) Three once-weekly intra-articular injections of Hylan G-F 20 significantly improve pain relief compared with placebo in patients with chronic idiopathic knee osteoarthritis: a single-centre, evaluator-blinded and patient-blinded, randomized controlled trial.
• [3] PubMed Central (2024) Evaluation of single and multiple hyaluronic acid injections at different concentrations with high molecular weight in the treatment of knee osteoarthritis.
• [4] PubMed Central (2024) EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics.
• [5] PubMed Central. (2025) Impact of Transitioning Elective Orthopedic Surgeries to the Ambulatory Setting on Acute-Care Hospital Operations and Quality.
• [6] Cipla Limited (2025) Cipla partners with Stempeutics, launches Stem Cell Therapy for Knee Osteoarthritis.
• [7] IBSA UK (2024) IBSA UK launches the latest generation of treatment options for musculoskeletal conditions in the UK.

This Report Addresses

• Market intelligence to enable structured strategic decision making across osteoarthritis care expansion and viscosupplementation portfolio planning
• Market size estimation and 10-year revenue forecasts from 2026 to 2036 for viscosupplementation demand
• Growth opportunity mapping across product classes and end-user treatment pools
• Segment and regional revenue forecasts aligned to the stated taxonomy and covered geographies
• Competition strategy assessment including supplier positioning, portfolio fit, and orthopedic channel coverage benchmarking
• Product and compliance tracking focused on treatment regimen design, specialist standards, and recurring-use expectations
• Regulatory impact analysis covering product-led therapy selection and provider-level protocol adoption in regulated care settings
• Market report delivery in PDF, Excel, PPT, and interactive dashboard formats for executive and operational use